Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 25;23:100353. doi: 10.1016/j.eclinm.2020.100353

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s)

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 4 — (A) Persistence of HPV-18 antibody titers (International Units per mL [IU/mL]) and (B) seroconversion rates in all subjects who received at least one dose of the vaccine (TVC). Seroconversion: percentage of subjects with an anti-HPV-18 VLP IgG antibody concentrations ≥3.2 IU/mL (by ELISA) ATP: according to protocol;D: Day; CI: confidence interval; ELISA: Enzyme-linked Immunosorbent Assay; GMC: geometric mean concentration; HIV: human immunodeficiency virus; HPV: human papillomavirus; IgG: immunoglobulin G; M: Month; n: number of subjects seroconverted; N: total number of subjects; VLP: virus-like particle; W: Week; WLWH: women living with HIV.